Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors.

Renal tumor heterogeneity studies have utilized the von Hippel-Lindau VHL gene to classify disease into molecularly defined subtypes to examine associations with etiologic risk factors and prognosis. The aim of this study was to provide a comprehensive analysis of VHL inactivation in clear cell rena...

Full description

Bibliographic Details
Main Authors: Lee E Moore, Michael L Nickerson, Paul Brennan, Jorge R Toro, Erich Jaeger, Jessica Rinsky, Summer S Han, David Zaridze, Vsevolod Matveev, Vladimir Janout, Hellena Kollarova, Vladimir Bencko, Marie Navratilova, Neonilia Szeszenia-Dabrowska, Dana Mates, Laura S Schmidt, Petra Lenz, Sara Karami, W Marston Linehan, Maria Merino, Stephen Chanock, Paolo Boffetta, Wong-Ho Chow, Frederic M Waldman, Nathaniel Rothman
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-10-01
Series:PLoS Genetics
Online Access:http://europepmc.org/articles/PMC3192834?pdf=render
id doaj-bd67a45cf52e4d689d24684d0c06fcef
record_format Article
spelling doaj-bd67a45cf52e4d689d24684d0c06fcef2020-11-24T21:41:38ZengPublic Library of Science (PLoS)PLoS Genetics1553-73901553-74042011-10-01710e100231210.1371/journal.pgen.1002312Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors.Lee E MooreMichael L NickersonPaul BrennanJorge R ToroErich JaegerJessica RinskySummer S HanDavid ZaridzeVsevolod MatveevVladimir JanoutHellena KollarovaVladimir BenckoMarie NavratilovaNeonilia Szeszenia-DabrowskaDana MatesLaura S SchmidtPetra LenzSara KaramiW Marston LinehanMaria MerinoStephen ChanockPaolo BoffettaWong-Ho ChowFrederic M WaldmanNathaniel RothmanRenal tumor heterogeneity studies have utilized the von Hippel-Lindau VHL gene to classify disease into molecularly defined subtypes to examine associations with etiologic risk factors and prognosis. The aim of this study was to provide a comprehensive analysis of VHL inactivation in clear cell renal tumors (ccRCC) and to evaluate relationships between VHL inactivation subgroups with renal cancer risk factors and VHL germline single nucleotide polymorphisms (SNPs). VHL genetic and epigenetic inactivation was examined among 507 sporadic RCC/470 ccRCC cases using endonuclease scanning and using bisulfite treatment and Sanger sequencing across 11 CpG sites within the VHL promoter. Case-only multivariate analyses were conducted to identify associations between alteration subtypes and risk factors. VHL inactivation, either through sequence alterations or promoter methylation in tumor DNA, was observed among 86.6% of ccRCC cases. Germline VHL SNPs and a haplotype were associated with promoter hypermethylation in tumor tissue (OR = 6.10; 95% CI: 2.28-16.35, p = 3.76E-4, p-global = 8E-5). Risk of having genetic VHL inactivation was inversely associated with smoking due to a higher proportion of wild-type ccRCC tumors [former: OR = 0.70 (0.20-1.31) and current: OR = 0.56 (0.32-0.99); P-trend = 0.04]. Alteration prevalence did not differ by histopathologic characteristics or occupational exposure to trichloroethylene. ccRCC cases with particular VHL germline polymorphisms were more likely to have VHL inactivation through promoter hypermethylation than through sequence alterations in tumor DNA, suggesting that the presence of these SNPs may represent an example of facilitated epigenetic variation (an inherited propensity towards epigenetic variation) in renal tissue. A proportion of tumors from current smokers lacked VHL alterations and may represent a biologically distinct clinical entity from inactivated cases.http://europepmc.org/articles/PMC3192834?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Lee E Moore
Michael L Nickerson
Paul Brennan
Jorge R Toro
Erich Jaeger
Jessica Rinsky
Summer S Han
David Zaridze
Vsevolod Matveev
Vladimir Janout
Hellena Kollarova
Vladimir Bencko
Marie Navratilova
Neonilia Szeszenia-Dabrowska
Dana Mates
Laura S Schmidt
Petra Lenz
Sara Karami
W Marston Linehan
Maria Merino
Stephen Chanock
Paolo Boffetta
Wong-Ho Chow
Frederic M Waldman
Nathaniel Rothman
spellingShingle Lee E Moore
Michael L Nickerson
Paul Brennan
Jorge R Toro
Erich Jaeger
Jessica Rinsky
Summer S Han
David Zaridze
Vsevolod Matveev
Vladimir Janout
Hellena Kollarova
Vladimir Bencko
Marie Navratilova
Neonilia Szeszenia-Dabrowska
Dana Mates
Laura S Schmidt
Petra Lenz
Sara Karami
W Marston Linehan
Maria Merino
Stephen Chanock
Paolo Boffetta
Wong-Ho Chow
Frederic M Waldman
Nathaniel Rothman
Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors.
PLoS Genetics
author_facet Lee E Moore
Michael L Nickerson
Paul Brennan
Jorge R Toro
Erich Jaeger
Jessica Rinsky
Summer S Han
David Zaridze
Vsevolod Matveev
Vladimir Janout
Hellena Kollarova
Vladimir Bencko
Marie Navratilova
Neonilia Szeszenia-Dabrowska
Dana Mates
Laura S Schmidt
Petra Lenz
Sara Karami
W Marston Linehan
Maria Merino
Stephen Chanock
Paolo Boffetta
Wong-Ho Chow
Frederic M Waldman
Nathaniel Rothman
author_sort Lee E Moore
title Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors.
title_short Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors.
title_full Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors.
title_fullStr Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors.
title_full_unstemmed Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors.
title_sort von hippel-lindau (vhl) inactivation in sporadic clear cell renal cancer: associations with germline vhl polymorphisms and etiologic risk factors.
publisher Public Library of Science (PLoS)
series PLoS Genetics
issn 1553-7390
1553-7404
publishDate 2011-10-01
description Renal tumor heterogeneity studies have utilized the von Hippel-Lindau VHL gene to classify disease into molecularly defined subtypes to examine associations with etiologic risk factors and prognosis. The aim of this study was to provide a comprehensive analysis of VHL inactivation in clear cell renal tumors (ccRCC) and to evaluate relationships between VHL inactivation subgroups with renal cancer risk factors and VHL germline single nucleotide polymorphisms (SNPs). VHL genetic and epigenetic inactivation was examined among 507 sporadic RCC/470 ccRCC cases using endonuclease scanning and using bisulfite treatment and Sanger sequencing across 11 CpG sites within the VHL promoter. Case-only multivariate analyses were conducted to identify associations between alteration subtypes and risk factors. VHL inactivation, either through sequence alterations or promoter methylation in tumor DNA, was observed among 86.6% of ccRCC cases. Germline VHL SNPs and a haplotype were associated with promoter hypermethylation in tumor tissue (OR = 6.10; 95% CI: 2.28-16.35, p = 3.76E-4, p-global = 8E-5). Risk of having genetic VHL inactivation was inversely associated with smoking due to a higher proportion of wild-type ccRCC tumors [former: OR = 0.70 (0.20-1.31) and current: OR = 0.56 (0.32-0.99); P-trend = 0.04]. Alteration prevalence did not differ by histopathologic characteristics or occupational exposure to trichloroethylene. ccRCC cases with particular VHL germline polymorphisms were more likely to have VHL inactivation through promoter hypermethylation than through sequence alterations in tumor DNA, suggesting that the presence of these SNPs may represent an example of facilitated epigenetic variation (an inherited propensity towards epigenetic variation) in renal tissue. A proportion of tumors from current smokers lacked VHL alterations and may represent a biologically distinct clinical entity from inactivated cases.
url http://europepmc.org/articles/PMC3192834?pdf=render
work_keys_str_mv AT leeemoore vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT michaellnickerson vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT paulbrennan vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT jorgertoro vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT erichjaeger vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT jessicarinsky vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT summershan vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT davidzaridze vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT vsevolodmatveev vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT vladimirjanout vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT hellenakollarova vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT vladimirbencko vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT marienavratilova vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT neoniliaszeszeniadabrowska vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT danamates vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT laurasschmidt vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT petralenz vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT sarakarami vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT wmarstonlinehan vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT mariamerino vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT stephenchanock vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT paoloboffetta vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT wonghochow vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT fredericmwaldman vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT nathanielrothman vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
_version_ 1725920791219929088